In HFpEF, the benefit of empagliflozin on a...

In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.

Abstract

SOURCE CITATION: Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322.

Authors

Fudim M; Van Spall HGC

Journal

Annals of Internal Medicine, Vol. 175, No. 10,

Publisher

American College of Physicians

Publication Date

October 1, 2022

DOI

10.7326/j22-0075

ISSN

1056-8751

Associated Experts

Harriette Van Spall

Associate Professor, FHSMED

Visit profile

Labels